SubHero Banner

Kineret® (anakinra) – Emergency use authorization granted

November 8, 2022 - The FDA issued an emergency use authorization (EUA) for Swedish Orphan Biovitrum AB’s (Sobi) Kineret (anakinra), for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults with positive results of direct SARS-CoV-2 viral testing with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor.

Download PDF